- Report
- March 2024
- 197 Pages
Global
From €3257EUR$3,374USD£2,794GBP
€3619EUR$3,749USD£3,104GBP
- Report
- November 2023
- 175 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Report
- April 2024
- 193 Pages
Global
From €5260EUR$5,450USD£4,512GBP
- Report
- November 2023
- 145 Pages
Global
From €2412EUR$2,499USD£2,069GBP
- Clinical Trials
- April 2024
- 170 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Report
- February 2024
- 180 Pages
Global
From €3813EUR$3,950USD£3,270GBP
- Report
- October 2023
- 145 Pages
Global
From €3040EUR$3,150USD£2,608GBP
- Report
- December 2023
- 140 Pages
Global
From €4295EUR$4,450USD£3,684GBP
- Report
- March 2024
- 184 Pages
Global
From €3257EUR$3,374USD£2,794GBP
€3619EUR$3,749USD£3,104GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1206EUR$1,250USD£1,035GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Report
- September 2023
- 161 Pages
Global
From €2413EUR$2,500USD£2,070GBP
- Report
- March 2024
- 188 Pages
Global
From €3257EUR$3,374USD£2,794GBP
€3619EUR$3,749USD£3,104GBP
- Report
- July 2023
- 180 Pages
Global
From €5743EUR$5,950USD£4,926GBP
- Report
- March 2024
- 148 Pages
Global
From €3763EUR$3,899USD£3,228GBP
- Report
- February 2024
- 114 Pages
Global
From €4585EUR$4,750USD£3,933GBP
- Clinical Trials
- April 2024
- 250 Pages
Global
From €2896EUR$3,000USD£2,484GBP
- Report
- August 2023
- 153 Pages
Global
From €7239EUR$7,500USD£6,210GBP
- Report
- June 2023
- 338 Pages
Global
From €7239EUR$7,500USD£6,210GBP
The Glaucoma Drug market is a subset of the Optical Disorders Drugs market, which includes medications used to treat a variety of eye conditions. Glaucoma is a group of eye diseases that cause damage to the optic nerve, resulting in vision loss. Glaucoma drugs are used to reduce intraocular pressure, which is the main risk factor for glaucoma. These drugs can be administered orally, topically, or through injections. Commonly used glaucoma drugs include prostaglandin analogs, beta blockers, alpha agonists, carbonic anhydrase inhibitors, and cholinergic agonists.
Some of the major companies in the Glaucoma Drug market include Allergan, Pfizer, Merck, Novartis, Bausch Health, Sun Pharmaceuticals, Santen Pharmaceuticals, and Alcon. Show Less Read more